Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.
暂无分享，去创建一个
M. Garami | I. Yaniv | T. Trahair | R. Luksch | R. Ladenstein | G. Laureys | P. Brock | W. Balwierz | V. Castel | P. Kogner | A. Pearson | D. Valteau Couanet | J. Mališ | V. Papadakis | E. Ruud | H. Schroeder | A. Forjaz de Lacerda | M. Beck Popovic | U. Poetschger | P. Bician | A. F. D. Lacerda | V. Castel | Toby Trahair | Walentyna Balwierz | R. Ladenstein | Penelope R. Brock | Isaac Yaniv | Josef Malis | Ellen Ruud | Per Kogner | Henrik Schroeder | M. B. Popovic | D. V. Couanet